Production (Stage)
Tonix Pharmaceuticals Holding Corp.
TNXP
$28.93
$2.539.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.93% | -8.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.93% | -8.50% | |||
| Cost of Revenue | -20.29% | -23.92% | |||
| Gross Profit | 6.22% | 10.42% | |||
| SG&A Expenses | -35.16% | 102.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.25% | 36.38% | |||
| Operating Income | 28.59% | -44.53% | |||
| Income Before Tax | 23.88% | -55.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.88% | -55.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.88% | -55.55% | |||
| EBIT | 28.59% | -44.53% | |||
| EBITDA | 27.65% | -42.97% | |||
| EPS Basic | 70.93% | 57.31% | |||
| Normalized Basic EPS | 74.54% | 57.31% | |||
| EPS Diluted | 70.92% | 57.31% | |||
| Normalized Diluted EPS | 74.54% | 57.31% | |||
| Average Basic Shares Outstanding | 161.86% | 264.38% | |||
| Average Diluted Shares Outstanding | 161.86% | 264.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||